SAA Assay Kit CLIA

Primary DI

06974521004387

Basic UDI-DI Code

B-06974521004387

Reference

SUPM045036

Device Types

Single use

Regulation

Eu Ivdd

Classification

Eu Ivd General

Status

On The Market

Manufacturer

Shenzhen Superbio Technology Co.,Ltd.

This kit is used for in vitro quantitative detection of serum amyloid protein A (SAA) in human serum, plasma or whole blood samples. Serum amyloid protein A (SAA) is a kind of acute protein and its concentration in the blood can rise sharply in several hours during the periods of inflammatory , infectious and non-infectious diseases. It can rise to 1000 times of the initial concentration. SAA is related to high-intensity lipoprotein (HDL) and it can regulate the metabolism of HDL in the inflammation period. A very important characteristic of SAA is that its decomposition product can settle in different organs in the form of amyloid protein A (AA) fibril, which is a kind of severe complications of chronic inflammatory diseases. Similar to C reactive protein (CRP), SAA can be tested to help diagnose inflammation, evaluate its activity and monitor its activity and treatment. However, SAA has a higher test accuracy than C reactive protein test of patients with virus infection, rejection reaction of kidney transplant (especially patients with immunosuppressive therapy) and patients with cystic fibrosis who are treated using adrenocortical hormone. Research shows that SAA is related to disease activity most closely among patients with inflammatory arthritis. Meanwhile, C reactive protein and SAA can be tested to improve the diagnostic sensitivity of infection. For patients with amyloid protein A amyloidosis, restoring the SAA level to normal can improve the state of illness.

Other on-the-market devices with the same classification (Eu Ivd General) and regulation (EU IVDD).